When one in every of Dr. Greg Gonzaba’s closest associates from medical faculty referred to as him out of the blue, Gonzaba anticipated a dialog about his follow and life in Austin. However fats had been build up in his pal’s liver undetected, till it was too late.
“He instructed me he was on hospice,” Gonzaba mentioned.
He died a number of months later, at 53.
Gonzaba, an inside medication doctor with Gonzaba Medical Group in San Antonio, has since seen a number of sufferers die from fatty liver illness over his 27 years in follow.
“Typically the households, they’re perplexed,” he mentioned. “They’re like, ‘What do you imply? You by no means instructed us we had this, and the place did this come from?’ It might probably sneak up on you if it’s not caught early.”
Metabolic dysfunction-associated steatohepatitis (MASH) happens when extra fats cells construct up within the liver, driving persistent irritation. It was previously referred to as non-alcoholic steatohepatitis (NASH). The situation is a subgroup of fatty liver illnesses, which additionally consists of alcohol-associated liver illness.
Gonzaba is now main efforts to recruit sufferers in San Antonio for a nationwide examine led by the Basis for the Nationwide Institutes of Well being (FNIH) seeking to discover higher methods to detect fats buildup within the liver sooner, and extra typically.
San Antonio was one in every of 4 websites chosen, Gonzaba mentioned, partly because of the excessive prevalence of comorbidities and threat components that usually accompany fatty liver illnesses, together with weight problems, diabetes and high-fat diets. It was additionally chosen for its vital Hispanic inhabitants, a gaggle that’s extra vulnerable to the illness on common.
MASH charges rising
MASH is on a dramatic rise within the U.S.
In 2000, 0.1% of liver transplants had been pushed by MASH nationally. In 2022, that quantity jumped to 16%, the main trigger after alcohol-driven liver illness solely, in line with a 2024 examine revealed within the Southern Medical Journal.
Different analysis means that MASH prevalence and mortality is rising and can proceed to rise by 2030 within the U.S. — pushed by rising charges of weight problems and diabetes, in addition to an ageing inhabitants. There may be additionally a genetic part to the illness.
A 2016 examine additionally discovered that Hispanic individuals residing in Cameron County in South Texas skilled liver cirrhosis practically 4 occasions the nationwide common, pushed by excessive charges of weight problems and diabetes. The examine additionally notes that Hispanics in South Texas have the very best incidence of liver most cancers within the nation.
“I do see quite a lot of Hispanic sufferers, and I see lots of people which might be obese, lots of people with diabetes,” mentioned Gonzaba, who practices out of Gonzaba Medical Group’s Northwest Clinic in San Antonio. “Consider it or not, nearly anybody that we do a liver scan on, their gallbladder for gallstones or take a look at their kidneys, we see fatty liver buildup.”
The excellent news is that fatty liver illness is treatable and reversible. The intervention for MASH is basically lifestyle-focused, however two not too long ago authorized medication are additionally accessible, together with the GLP-1 agonist semaglutide, authorized to deal with MASH in 2025.
To greatest fight the illness, “When you’re obese, shed weight. When you’re a diabetic, management your diabetes, and in case you eat quite a lot of meals that’s excessive in fats, change your weight loss plan and get common train,” Gonzaba mentioned. “In some individuals, that’s greater than sufficient to even reverse this.”
The dangerous information is that a good portion of sufferers gained’t know they’ve MASH till it’s too late, largely due to insufficient diagnostics.
Skipping the needle
MASH at present requires a prolonged prognosis. This entails imperfect blood exams that may miss sure sufferers, imaging and in the end a liver biopsy, a bedside process that requires inserting a hole needle by the pores and skin into the liver to get a pattern of liver tissue.
“That’s slightly extra invasive,” Gonzaba mentioned. “It may be painful and costly.”
The FNIH’s Biomarkers Consortium is in search of to validate new biomarkers to detect MASH with out the necessity for a liver biopsy, in the end serving to catch this earlier and in additional sufferers earlier than vital liver harm happens.
The group is main successive research in search of to seek out dependable non-invasive methods to diagnose and deal with liver illness. This consists of the NIMBLE challenge, which the Gonzaba Medical Group helps recruit sufferers for.
The FNIH laid out its motivations for locating higher diagnostics for MASH in a 2026 correspondence in Nature Communications.
“The established order has many limitations,” the authors wrote. “It requires liver biopsy, which is invasive and related to the potential for extreme morbidity and even loss of life, and is additional negatively impacted by sampling and observer variability. These have contributed to excessive display screen failure charges for medical trials.
“Collectively these represent a significant barrier to drug growth for this public well being risk.”
Gonzaba Medical Group helps recruit sufferers throughout its San Antonio clinics for the bigger examine that can be carried out. Up to now, the medical group has about 10 contributors.
As a result of the factors are so strict, discovering contributors is a prolonged course of. Examine contributors are compensated for his or her time. Gonzaba and his crew are aiming to recruit roughly 200 sufferers.
“Catching it earlier will be life-saving for lots of people,” Gonzaba mentioned.
